Clinical pharmacology review of escitalopram for the treatment of depression

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 1, 2014, Pages 121-128

  Pastoor, Devin ^a   Gobburu, Joga ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Citalopram; Depression; Escitalopram; Food and Drug Administration; Major depressive disorder; Regulatory approval; Selective serotonin reuptake inhibitor

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESCITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PHARMACOLOGY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EJACULATION DISORDER; FATIGUE; FOLLOW UP; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACODYNAMICS; PSYCHOPHARMACOTHERAPY; QT INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SWEATING;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DRUG EVALUATION, PRECLINICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84890407522     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.863873     Document Type: Article

References (32)

1. World Health Organization.Depression Fact Sheet. 2012. Available from: Http://www.who.int/mediacentre/factsheets/ fs369/en/index.html
2. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe. J Ment Health Policy Econ 2006;9(2):87-98
3. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: Results from the World Health Surveys. Lancet 2007;370(9590):851-8
4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-105
5. Thase ME. Treatment of severe depression. J Clin Psychiatry 2000;61(Suppl 1):17-25
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. American Psychiatric Assocation; Washington, DC; 2000
7. FDA. Escitalopram Review. Available from: Http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm? fuseaction=Search.Label-ApprovalHistory [Accessed 12 April 2013
8. Cipriani A, Purgato M, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2012;7(4):CD006534
9. Kirino E. Escitalopram for the management of major depressive disorder: A review of its efficacy, safety, and patient acceptability. Patient Prefer. Adherence 2012;6:853-61
10. Ali MK, Lam RW. Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2011;7:39-49
11. Mendlewicz J. Optimising antidepressant use in clinical practice: Towards criteria for antidepressant selection. Br J Psychiatry Suppl 2001;42:S1-3
12. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004;38(6):389-407
13. Roose SP. Compliance: The impact of adverse events and tolerability on the physician's treatment decisions. Eur Neuropsychopharmacol 2003;13(Suppl 3):S85-92
14. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50(5):345-50
15. Hyttel J, Bøgesø KP, Perregaard J, Sánchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88(2):157-60
16. Chen F, Larsen MB, Sánchez C, et al. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005;15(2):193-8
17. Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004;174(2):163-76
18. Neubauer HA, Hansen CG, Wiborg O. Dissection of an allosteric mechanism on the serotonin transporter: A cross-species study. Mol Pharmacol 2006;69(4):1242-50
19. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50(5):345-50
20. Sánchez C, Bergqvist PBF, Brennum LT, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003;167(4):353-62
21. El Mansari M, Sánchez C, Chouvet G, et al. Effects of acute and long-Term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005;30(7):1269-77
22. Søgaard B, Mengel H, Rao N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005;45(12):1400-6
23. Klein N, Sacher J, Geiss-Granadia T, et al. Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: An [123I]ADAM SPECT study. Psychopharmacology (Berl) 2007;191(2):333-9
24. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999;46(6):839-49
25. Von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (Scitalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29(8):1102-9
26. Baumann P. Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 1996;11(Suppl 1):5-11
27. Rudberg I, Hendset M, Uthus LH, et al. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (Scitalopram). Ther Drug Monit 2006;28(1):102-5
28. Herrlin K, Yasui-Furukori N, Tybring G, et al. Metabolism of citalopram enantiomers in CYP2C19/ CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003;56(4):415-21
29. Spigset O, Hägg S, Stegmayr B, et al. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000;56(9-10):699-703
30. Carlsson B, Olsson G, Reis M, et al. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit 2001;23(6):658-64
31. FDA Safety Communication. 2012.Available from: Http://www.fda.gov/ drugs/drugsafety/ucm297391.htm [Accessed 21 June 2013
32. Pedersen AG. Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 2005;20(3):139-43